Eggs of the Future: Swedish Hens Fed Mycoprotein Instead of Soy

Feed represents up to 80% of the climate impact in Swedish egg production. Axfoundation and SLU are testing a soy-free laying-hen feed using mycoprotein produced from food-industry side streams to reduce environmental impact; the limited-run eggs will be sold at Urban Deli.

Analysis

Winners will be firms that control the fermentation / microbial ingredient stack (strain development, scale fermentation, downstream drying) rather than raw soybean logistics. If producers can localize feed inputs using low-cost side streams, freight-exposed soybean meal margins in Northern Europe could compress by a sustained 5–15% over 2–4 years, shifting value from crushers/traders to ingredient tech providers and toll-manufacturers.

The path to commercial scale is a sequence of short, testable catalysts: nutrition/laying-performance parity in replicated trials (months), regulatory feed approvals and supply‑contract wins (6–18 months), and capex cycles to build dedicated fermenters (18–48 months). Reversals are straightforward — a contamination or nutrient deficiency in trials, or a >20% fall in soybean prices, would stall procurement commitments and keep soymeal demand intact.

Consensus underestimates formulation complexity and capital intensity. Replacing soybean is not just a protein swap; bioavailability of limiting amino acids, energy density, and pellet stability typically force continued blending with conventional meals and synthetic amino acids, meaning adoption is incremental and likely concentrated in premium, traceable product lines (2–5% penetration in first 1–3 years) rather than a broad immediate displacement.

For corporates, the strategic play is M&A or long-term tolling agreements: incumbents with balance-sheet flexibility can retrofit crushing/processing assets to capture higher-margin post-fermentation steps. Retailers and branded egg producers can monetize ESG willingness-to-pay quickly via limited drops and price tests; that revenue premium is the clearest short-term monetization route (quarters), while commodity impacts play out over years.

Key Decisions for Investors

• Long NZYM-B (Novozymes) — timeframe 6–24 months. Exposure to enzymes, microbial solutions and fermentation know-how positions it to capture margin migration from commodity crushers. Target gain 30–50% if European feed formulators adopt fermentation ingredients at scale; cut half at 15% drawdown given execution/capex risk.
• Long MNDY (Monde Nissin) — timeframe 12–36 months. Direct upside from scaling mycoprotein applications (B2B feed licensing or ingredient sales) and consumer-brand leverage. Risk/reward ~2:1 factoring regulatory and commercial scaling uncertainty; set a 20% stop.
• Pair trade: Long NZYM-B / Short ADM (ADM) — timeframe 12–36 months. Play margin rotation from bulk soy/crushing (ADM) toward ingredient tech. Size as a market‑neutral pair; target asymmetric payoff if soymeal demand in EU falls 5–10%; tighten if soybean prices collapse >20%.
• Tactical retailer/producer play: Long CALM (Cal‑Maine Foods) small size — timeframe 3–12 months. Buy weakness around industry shock events to capture premium-egg pricing tests and limited-edition ESG SKUs; limited position (1–2% book) because avian disease and feed shocks create high idiosyncratic risk.